Drug intelligence / Profile preview

TAK-379

Development stage: Discontinued
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

TAK-379 is a small molecule agonist of the G protein-coupled receptor 120 (GPR120), also known as free fatty acid receptor 4 (FFAR4). Developed by Takeda, the compound was designed to treat type 2 diabetes by leveraging the insulin-sensitizing and anti-inflammatory properties of GPR120 activation. GPR120 is a receptor for long-chain omega-3 fatty acids and is involved in the regulation of metabolic homeostasis. TAK-379 reached Phase 2 clinical trials (NCT02324647), where it was evaluated for efficacy and safety in subjects with type 2 diabetes. However, the program was subsequently discontinued and is no longer present in Takeda's active development pipeline.

Targets

FFAR4 (Free fatty acid receptor 4)

Beyond the preview

Go deeper on TAK-379.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TAK-379.

Explore the full profile